546 DUAL INHIBITION OFII-1-INDUCED NF-κB ACTIVATION AND iNOS ENZYME ACTIVITY IN HUMAN CHONDROCYTES BY NATURAL AND COMMERCIAL α-PINENE  by Gonçalves, J. et al.
Poster Presentations – Therapy – Pharmacologic S231
Figure 1. Change in pain scores on the 50-foot Walk Test from baseline
to week 26 ITT population.
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Purpose: Within the last few decades the concept of disease modifying
drugs (DMOAD) have been explored as alternative therapeutic treatment
modalities for osteoarthritis (OA). From the results of previous in vitro
and animal model studies, we have proposed that the spectrum of phar-
macological activities exhibited by Sodium Pentosan Polysulfate (NaPPS)
would qualify it as a DMOAD. However human clinical evidence to support
this proposition was a few. To assess the efﬁcacy, safety, and patient
satisfaction with a series of subcutaneous injections of NaPPS in the
patients who reported knee joint OA-associated pain, loss of ROM, and
disability that interfered with daily life and work
Methods: NaPPS is a semi-synthetic drug manufactured from beech-
wood hemicellulose by sulfate esteriﬁcation of the xylopyranose hydroxyl
groups. It has an average mean molecular weight of 5700Da. NaPPS in
this study was manufactured and supplied in injectable vials (100mg/ml)
by bene-Arzneimittel GmbH, Munich, Germany.
The open trial was undertaken with 20 patients with knee OA. Patients
were clinically assessed at entry and 1, 2, 3, 4, 8, 12, 16, 24 and 52 weeks
with physical examination and VAS for stiffness, pain at rest or walking,
ROM exercises, walking up and down stairs. A modiﬁed WOMAC OA
index was used for lifestyle parameters. Degradation of type II Collagen
(C2C) in Blood was measured with an ELISA kit, in accordance with the
manufacturer’s instructions.
Before the treatment, 2 weeks of NSAIDs washout period was made,
if necessary. Treatment consisted of 6 weekly subcutaneous injections
(sc) of NaPPS (2mg/kg). The protocol and written informed consent for
studies involving human subjects were approved by the review board in
our university. The statistical signiﬁcance, compared with the value at
entry, was determined by one way ANOVA and Dunnett’s method.
Results: The attribution of patients was as following: The average year
was 63 years old, All cases were female, were included in grade 1 to
2 according the classiﬁcation of Kellgren and Lawrence. The average of
WOMAC score at the ﬁrst visit was 37.0. All cases could be followed for
one year.
The dose of this PPS effected the blood coagulation test, but the value
in the study was within safety area. A tiny abnormal ﬁnding is noted in
serum chemistry: ie: serum triglyceride 1 hr after injection., but it was
reduced quickly in followed up period.
The hydroarthroses were reduced quickly in all cases. ROM of the knee
joint was improved. The clinical assessments, i.e. knee ﬂexion, pain at
walking, pain just after climb up and down stairs, pain just after ROM
exercise were improved signiﬁcantly. The concentration of C2C in Blood
were decreased signiﬁcantly. The clinical effect was continued for almost
one year.
The improvement of X ray ﬁndings could not detected.
In the previous vitro study, PPS reduced cartilage degradation by directly
and indirectly affecting these inﬂammatory mediators such as MMP-3.
PPS increased both the synthesis and the molecular weight of hyaluro-
nan. PPS had anti-inﬂamatory function. As the results of C2C in Blood,
quickly reducion of hydroarthroses and improvement of the knee joint
R.O.M., our result was compatible to the above vitro study
Conclusions: The availability, safety of NaPPS for knee osteo-arthlitis
patients and satisfaction level of patients was studied.
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Purpose: Our previous studies showed that the essential oil from the
leaves of Juniperus oxycedrus has potential value as a source of new
compounds capable of targeting the NF-úB signaling pathway in OA
chondrocytes. Upon fractionation, a fraction designated F3 proved to be
effective in reducing Il-1-induced NF-úB activation and NO production.
Since that fraction contains predominantly a racemic mixture of (+)-
and (−)-a-pinene, we compared its ability to inhibit those Il-1-induced
responses with those of pure commercial racemic a-pinene, (+)- and
(−)-a-pinene enantiomers, as well as with that of turpentine oil, another
natural source of racemic a-pinene. b-pinene was also tested.
Methods: The essential oil from Juniperus oxycedrus leaves was frac-
tionated by liquid chromatography and analyzed by gas chromatogra-
phy and gas chromatography-mass spectroscopy . a-pinene constitutes
approximately 92% of F3. Human chondrocytes were isolated from the
femoral condyles of multi-organ donors and used to evaluate the ability
of F3, turpentine oil and pure pinene isomers to inhibit Il-1-induced
NO production. The human chondrocytic cell line, C-28/I2, was used to
evaluate NF-úB activation. Both cell culture types were treated for 30min
with the essential oils or fraction, in two different dilutions, followed by
treatment with Il-1b (30 ng/ml) for 30min or 18 h to evaluate, respectively,
the cytoplasmic levels of IúB-a by western blot, or NO production by
the Griess reaction. To determine whether the test compounds have any
direct effect on iNOS enzyme activity, NO production was evaluated in
cell cultures pretreated with Il-1, 30 ng/ml, to induce the expression of the
enzyme before the addition of the test compounds. The MTT reduction
assay was used to rule out cytotoxic effects.
Table 1: Effect of pretreatment with natural and synthetic pinene isomers on Il-1-induced NO
production
NO production induced by Il-1b 30 ng/ml
Test compound dilution 1:7500 Test compound dilution 1:5000
No pretreatment 100.0±6.0%
Commercial racemic a-pinene 58.5±7.5% 40.6±3.4%
(+)-a-pinene 56.2±10.8% 30.1±2.9%
(−)-a-pinene 63.4±7.8% 57.3±6.0%
b-pinene 82.9±13.7% 76.7±14.7%
F3 51.4±7.3% 11.3±0.4%
Turpentine oil 71.8±3.5% 51.2±1.9%
Results: As shown in the table, F3, containing racemic a-pinene from
natural origin, is the most effective in reducing Il-1-induced NO produc-
tion (11.3%±0.4). When added to the chondrocyte cultures 18 h after
addition of Il-1, F3 also reduced NO production, although with a lower
magnitude than when added to the cell cultures before Il-1. Among the
pure compounds, (+)-a-pinene was the most effective in reducing Il-1-
induced NO production (30.1%±2.9), either when added before or after
Il-1. b-Pinene was only slightly active. F3 and (+)-a-pinene were also the
most effective in preventing Il-1-induced IúB-a degradation.
Conclusions: (+)-a-Pinene is more active than its (−) enantiomer. Since
F3 achieved a greater inhibition of both NF-úB activation and NO
production than the commercial racemic a-pinene or the (+)-a-pinene
enantiomer, it is possible that other minor components of that fraction
will also be active. The results obtained also indicate that a-pinene acts
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both at the transcriptional level and at the level of iNOS enzyme activity.
Whether a-pinene is selective for iNOS or also inhibits the other NOS
isoforms will have to be determined. The dual mode of action of a-pinene
may represent an advantage over other agents that either inhibit NF-úB
activation or iNOS activity, making it promising as an anti-osteoarthritic
drug.
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Purpose: This study investigated using injectable, drug-loaded micro-
spheres to prolong the delivery of small molecule drugs to the intraartic-
ular (IA) space of the knee joint while minimizing systemic exposure.
Biocompatibility was evaluated and in vitro drug release rates were
compared to in vivo release and bioactivity.
Methods: Microsphere characterization: Drugs were either obtained
commercially (naproxen and celecoxib) or prepared by known published
methods (cipemastat). Poly(D,L-lactide) (PLA) microspheres loaded with
either naproxen (NSAID), celecoxib (COX-2 inhibitor), or cipemastat
(MMP inhibitor) were prepared using an oil in oil emulsion method and
fractionated to a 38−75 mm size range. In vitro release was conducted
under physiologic conditions (PBS, 37ºC); drug release was quantiﬁed
by HPLC.
Biocompatibility: PLA microspheres suspended in hylan G-F 20 (5% w/v;
50ml) were injected into stiﬂe joints of normal guinea pigs. At 1 week
and 4 months after injection, gross morphometric analysis (joint width)
and histologic assessments of decalciﬁed cartilage, bone, and synovium
were performed to assess the acute and chronic biocompatibility of the
delivery system.
PK and bioactivity: Naproxen, celecoxib, and cipemastat loaded PLA
microspheres were administered to the knee joints of rabbits 4 weeks after
ACL transection. Plasma drug levels were monitored over 4 days after IA
injection to establish systemic PK proﬁles. At 4 days post-injection, drug
levels were assessed in local tissues. At 2 weeks post-injection, PGE-2
levels in synovial ﬂuid were measured to assess the relative bioactivities
of released celecoxib and naproxen.
Figure 1. PGE-2 levels in synovial ﬂuid.
Results: Microsphere charcterization: Naproxen, celecoxib and cipemas-
tat showed completed release from microspheres over 7, 30 and 45 days,
respectively giving associated half-lives of <1, 8, and 24 days.
Biocompatibility: Placebo microspheres showed median total synovial
and synovial inﬂammation scores equivalent to the control (hylan G-F 20).
Similarly, microspheres were not associated with any increased incidence
or severity of articular cartilage degeneration relative to the naive joints.
PK and bioactivity: Plasma PK proﬁles of drug released from micro-
spheres mimicked in vitro release proﬁles. At four days, drug levels in
joint tissues greatly exceeded plasma levels with naproxen, celecoxib, and
cipemastat showing 5.3, 38.2 and 22.4mg/mL in synovium, 1.7, 10.2 and
0.075mg/mL in synovial ﬂuid and 0.035, 0.009 and 0.007 mg/mL in plasma,
respectively. At day 14, PGE-2 levels were lower in celecoxib treated
OA joints than in either control or naproxen treated joints, suggesting
maintenance of COX-2 inhibitory activity, although this difference did not
reach statistical signiﬁcance.
Conclusions: PLA microspheres are well-tolerated in the IA space as
evidenced by histologic analysis of joint tissues. In addition, microspheres
targeted drugs to the IA space by providing therapeutic levels to local
tissues with minimal systemic exposure. As predicted by in vitro release
proﬁles, local, sustained delivery of celecoxib may have been effective at
suppressing PGE-2 levels in synovial ﬂuid over 14 days, while naproxen,
whose IA residence time was predicted to be no longer than 7 days, did
not have this effect.
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Purpose: In the course of prescribing chondroitin sulphate (CS) for the
treatment of knee osteoarthritis (KOA), it was observed that patients with
concomitant psoriasis (Ps) experienced a marked improvement of the
skin lesions. The aim of this pilot clinical trial was to assess the effects
of CS in patients with KOA and Ps.
Methods: 129 outpatients were enrolled in this multicentre, randomized,
double-blind, placebo (PBO) controlled clinical trial and received CS
800mg (Condrosan®, Bioibe´rica, Barcelona) once-a-day for a 3-month
treatment course. Patients were diagnosed with KOA according to
ACR criteria, radiological Kellgren-Lawrence score I-III, knee pain with
Huskisson’s VAS 30mm and plaque Ps with Psoriasis Area and
Severity Index (PASI) 5. The co-primary efﬁcacy outcomes were the
Huskisson’s VAS and the PASI. Joint and skin secondary parameters
included Lequesne’s algo-functional index, acetaminophen consumption,
Overall Lesion Severity Scale (OLS), Physician’s Global Assessment
(PGA) and evaluation of skin biopsies specimens. Quality-of-life was
determined with the SF-36 health survey and the Dermatology Life Quality
Index (DLQI). Global efﬁcacy and safety were evaluated by investigators
and patients with a semi-quantitative scale. These outcome measures
were assessed using ITT and PP and an ANCOVA was performed for all
statistical tests.
Results: At baseline, the study groups had moderate-severe KOA and
Ps and were balanced with respect to demographic and clinical variables.
CS was more effective than PBO in improving Huskisson’s VAS with
31.35±2.83mm in the CS group and 43.15±2.93mm for the PBO after
12 weeks of treatment (p< 0.01). The data regarding all the secondary
efﬁcacy parameters in rheumatology conﬁrmed the effect of CS with
statistical signiﬁcance at several end-points. There was a decrease in
acetaminophen consumption with 42.9% of patients using acetaminophen
in the CS group vs 64.0% in the PBO group at the end of the study
(p< 0.05). CS experienced a decrease of 4.57 points in the Lequesne’s
index vs 3.81 in the PBO group (p< 0.05).
After treatment with CS, patients experienced a mean decrease in PASI
score of 32.9%, without statistical signiﬁcance with respect to PBO.
However, the analysis of the different body areas affected with psoriatic
lesions determined with PGA showed that CS treatment improved plantar
Ps after 3 months treatment in 86.7% patients treated with CS vs 26.7%
in the PBO group (p< 0.05).
CS treatment improved quality of life in patients with both knee OA and
Ps, with statistical signiﬁcance vs PBO after 12 weeks treatment in some
subscales of both SF-36 and DLQI.
Tolerability was very good in both treatment groups. Adverse events
were infrequent and evenly distributed among groups. The PP analysis
conﬁrmed the results obtained by the ITT analysis.
Conclusions: The ﬁndings of this clinical trial conﬁrm the efﬁcacy and
safety of CS as a Symptomatic Slow-Acting Drug for Osteoarthritis
(SySADOA) reducing pain, improving physical function and quality of
life in patients with KOA. In view of the positive results with CS in the
treatment of plantar Ps, further studies should be performed to conﬁrm
the role of CS in this dermatologic disease. Moreover, the use of CS
could represent a special beneﬁt in patients with both pathologies since
NSAIDs have been reported to exacerbate preexisting Ps.
